Official: 17 World States Import Iran-Made Biotech Medicine
Secretary of the Biotechnology Development Headquarters of the Iranian Vice-Presidency for Science, Technology and Knowledge-Based Economy Mostafa Qaneyee put the current value of the nanotechnology medicines exported from Iran to other countries at above $200 million.
He noted that the government of President Massoud Pezeshkian is trying to indigenize the largest high-value products, including insulin and plasma, within the next two years and solve the existing problems.
Relevant reports said in August that an Iranian knowledge-based company had acquired the formulation of the production of medicines for rare diseases based on biotechnology and has managed to export them to 15 countries.
“Most of these drugs are prescribed to treat certain patients with rare diseases. The technology used in these drugs is based on biological technologies,” said Mohammad Safariun, the CEO of the pharmaceutical company in an interview with local Iranian media.
He then said that ‘Factor VIII’ is the latest product of the company which is an essential blood clotting protein.
The active substance in Advate, octocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot. Patients with haemophilia A lack factor VIII, and this causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Safariun pointed to AryoSeven™ as a safe Iranian recombinant activated factor VII as the other product of their company. It is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot. Factor VIIa is to be given only by or under the direct supervision of your doctor.
4155/v
